The 25 most significantly associated diseases after IL-17A treatment in chondrocytes included juvenile arthritis, experimental arthritis, musculoskeletal diseases, anoxia, and hyperalgesia (Figure 4A) In synovial fibroblasts the 25 most significantly associated diseases after IL-17A treatment included experimental arthritis, knee osteoarthritis, and pain, but mostly included IL-17 associated diseases including lung disease, viral bronchiolitis, and respiratory syncytial virus infections (Figure 4B). This evidence concerns the gene IL17A and musculoskeletal system disorder.